Document is current
Any future updates will be listed below
-
Authors
Huertas-Nieto, Sergio
Moraga-Yébenes, Ana
Zamora-Pérez, Lydia
Moreno, Guillermo
Maneiro-Melón, Nicolás
Sarnago-Cebada, Fernando
Kadir, Berk Feyzi
Medina, Aitana
García-Martín, Rosa María
Lizasoain, Ignacio
Bueno, Héctor https://orcid.org/0000-0003-0277-7596
,
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI21/01572)
Sociedad Española de Cardiología (SECFEC-INV-TRL-20-014)
Fondation Leducq (TNE-21CVD04)
RICORS-ICTUS (RD21/0006/0001)
I+12-Fortalece (FORT23/00023)
- License Information
-
More Information
Article History
Received: 14 June 2025
Accepted: 1 August 2025
First Online: 3 September 2025
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the Hospital Universitario 12 de Octubre (Protocol CEim 20/343, approved on 14 July 2020) and with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
: Dr. Bueno receives research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), the Spanish Society of Cardiology, AstraZeneca, Boehringer Ingelheim, and Janssen; and has previously received consulting and speaking fees from Novo Nordisk and Organon. Dr. Lizasoain reports receiving research grants from the Leducq Trans-Atlantic Network of Excellence on Circadian Effects in Stroke; the Instituto de Salud Carlos III, co-financed by the European Regional Development Fund “A Way to Make Europe”; the Cooperative Research Networks for Health Outcomes (RICORS-ICTUS); and the FORTALECE program of Instituto imas12. All other authors declare no conflicts of interest.
